Nov 2 2010
NanoScale Corporation (NanoScale®), a leader in advanced chemistry products, services, and technologies, today announced it has been awarded a contract to develop and optimize functionalized nanoparticles for imaging of breast cancer by fluorescence optical imaging.
Effective cancer surgery requires that all cancerous tissue be removed. However, the visual difference between cancerous and healthy tissue is subtle, often forcing the surgeon to remove excess tissue. NanoScale is leading a team comprising universities and companies from Kansas to develop and optimize functionalized nanoparticles that will allow for the diagnosis of breast cancer by fluorescence optical imaging. This technique will provide the surgeon an immediate differentiation between cancerous and non-cancerous tissues before any tissue is removed.
“This technique will provide surgeons an improved margin of tissue identification and cancer detection resulting in superior patient treatment and recovery,” said Olga Koper, Ph.D., NanoScale’s Chief Technology Officer.
The Phase II SBIR contract is financed 100% by Federal funding at the cost of $1 million. This project has been funded in whole or in part with Federal funds from the National Cancer Institute, National Institutes of Health, Department of Health and Human Services, under Contract No. HHSN261201000111C.
NanoScale Corporation develops and provides high performance advanced chemistry materials and related services to Customers worldwide. The Company holds a substantial intellectual property portfolio which includes its patented NanoActive®, FAST-ACT®, ChemKlenz®, OdorKlenz®, and SpillKlenz™ product lines and systems. NanoScale produces and sells a wide variety of NanoActive brand nanocrystalline materials in forms that include dry powders, granules, and liquid suspensions. FAST-ACT, ChemKlenz, and OdorKlenz Systems are sold for the prevention, containment, elimination, and remediation of toxic and noxious chemicals, odors, and related applications.